Skip to the page

Data / Drug companies / Amneal Pharmaceuticals of New York LLC

Amneal Pharmaceuticals of New York LLC: 116 products in the FDA NDC directory, labeler code 0115

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Amneal Pharmaceuticals of New York LLC (labeler code 0115) lists 116 products in the FDA National Drug Code Directory, covering 38 finished drugs by generic name. By type: 116 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 1, 2025.

The request: Watch Amneal Pharmaceuticals of New York LLC (FDA labeler code 0115): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0115
Products in commercial distribution
116
Packages
209
Finished drugs by generic name
38
Prescription products
116
Over the counter products
0
Controlled substance products
Schedule II 40, Schedule III 2
Flagged as original packager
108 of 108 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
October 17, 1974
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)10792.2%
Authorized generics (NDA)86.9%
New drug applications (NDA)10.9%

Products by type

TypeProductsShare
Prescription drugs116100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Capsule, extended release2925%
Tablet2824.1%
Capsule1916.4%
Tablet, film coated, extended release108.6%
Tablet, orally disintegrating86.9%
Tablet, film coated65.2%
Suspension43.4%
Solution32.6%
Capsule, delayed release21.7%
Powder, for suspension21.7%
Injection21.7%
Tablet, coated21.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Tamsulosin Hydrochloride0115-8211CapsuleGeneric drugs (ANDA)April 1, 2025
Fenofibric Acid0115-1325Capsule, delayed releaseGeneric drugs (ANDA)June 1, 2024
Fenofibric Acid0115-1324Capsule, delayed releaseGeneric drugs (ANDA)June 1, 2024
Carvedilol Phosphate0115-1251Capsule, extended releaseGeneric drugs (ANDA)January 1, 2024
Carvedilol Phosphate0115-1250Capsule, extended releaseGeneric drugs (ANDA)January 1, 2024
Carvedilol Phosphate0115-1249Capsule, extended releaseGeneric drugs (ANDA)January 1, 2024
Carvedilol Phosphate0115-1248Capsule, extended releaseGeneric drugs (ANDA)January 1, 2024
Colesevelam hydrochloride0115-1864For suspensionGeneric drugs (ANDA)January 20, 2023
Pyridostigmine Bromide0115-2134TabletGeneric drugs (ANDA)August 8, 2022
Chloroquine Phosphate0115-7010TabletGeneric drugs (ANDA)May 10, 2022
Chloroquine Phosphate0115-2790TabletGeneric drugs (ANDA)May 10, 2022
Rimantadine Hydrochloride0115-1911Tablet, film coatedGeneric drugs (ANDA)November 16, 2021
Dipyridamole0115-1072TabletGeneric drugs (ANDA)August 30, 2021
Dipyridamole0115-1071TabletGeneric drugs (ANDA)August 30, 2021
Dipyridamole0115-1070TabletGeneric drugs (ANDA)August 30, 2021
Colestipol hydrochloride0115-5211Tablet, film coatedGeneric drugs (ANDA)August 17, 2021
Sevelamer carbonate0115-1366Powder, for suspensionGeneric drugs (ANDA)November 20, 2020
Sevelamer carbonate0115-1365Powder, for suspensionGeneric drugs (ANDA)November 20, 2020
Cyclobenzaprine Hydrochloride0115-1437Capsule, extended releaseAuthorized generics (NDA)March 1, 2019
Cyclobenzaprine Hydrochloride0115-1436Capsule, extended releaseAuthorized generics (NDA)March 1, 2019
Lamotrigine0115-9942Tablet, orally disintegratingGeneric drugs (ANDA)December 27, 2018
Lamotrigine0115-9941Tablet, orally disintegratingGeneric drugs (ANDA)December 27, 2018
Lamotrigine0115-9940Tablet, orally disintegratingGeneric drugs (ANDA)December 27, 2018
Lamotrigine0115-9939Tablet, orally disintegratingGeneric drugs (ANDA)December 27, 2018
Morphine Sulfate0115-1479Capsule, extended releaseGeneric drugs (ANDA)October 5, 2018

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.